Gilbert Ledesma, MD
Family Medicine · Arlington, TXNPI 1720045842
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Johnson & Johnson at 39.9% of the total. Reporting peaked in 2019 at $17,817 and has fallen 99.5% since, to $88 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 623 payments — averaging $55.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$14K
- AbbVie$5K
- Genentech USA, Inc.$3K
- Novo Nordisk$3K
- Boehringer Ingelheim International GmbH$2K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- plus $6K from 42 others
Across 1,247 payments — averaging $919.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$826K
- AbbVie$271K
- AstraZeneca$34K
- Alnylam Pharmaceuticals Inc.$9K
- Boehringer Ingelheim$3K
- Astrazeneca UK Limited$3K
What the payments were for
- Consulting fees$2,8208%
- Speaking & faculty fees$20,37359%
- Travel & lodging$1,8155%
- Food & beverage$9,19027%
- Education$1931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,391 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $195,598 |
| FarxigaDapagliflozin Propanediol | 72 | $92,747 |
| MounjaroTirzepatide | 45 | $57,205 |
| JanuviaSitagliptin Phosphate | 37 | $56,938 |
| JardianceEmpagliflozin | 41 | $55,720 |
| EliquisApixaban | 51 | $45,669 |
| RybelsusSemaglutide | 11 | $17,703 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $16,708 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $14,605 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $13,780 |
| MyrbetriqMirabegron | 18 | $12,685 |
| LinzessLinaclotide | 17 | $11,447 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $11,199 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,753 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $5,832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,567 | $213,302137 claims |
| AstraZenecaFarxiga, Symbicort | $829 | $106,527124 claims |
| MerckJanuvia, Janumet Xr | $191 | $71,54352 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $400 | $62,47355 claims |
| Lilly USA, LLCMounjaro | $373 | $57,20545 claims |
| PfizerEliquis | $241 | $45,66951 claims |
| GSKBreo Ellipta, Anoro Ellipta, Incruse Ellipta | $504 | $21,25253 claims |
| AbbVieLinzess, Synthroid | $4,912 | $14,08753 claims |
| Astellas Pharma US IncMyrbetriq | $111 | $12,68518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Arlington
- Bradley WassonArlington$734K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.